Company intelligence / Profile preview

Bethesda Resources

Bethesda, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Bethesda Resources was a clinical-stage biotechnology company primarily focused on the development of retinoid-based therapies for oncology indications. The company is most notable for its role in the early development and intellectual property management of bexarotene, a selective retinoid X receptor (RXR) agonist. Bexarotene was eventually approved by the FDA under the brand name Targretin for the treatment of cutaneous T-cell lymphoma (CTCL). Bethesda Resources was ultimately acquired by Ligand Pharmaceuticals, which integrated the company's retinoid research and assets into its own oncology portfolio.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Ligand Pharmaceuticals

Beyond the preview

Go deeper on Bethesda Resources.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bethesda Resources.

Explore the full profile